Sunday, 25 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
NewCo Model: China's Innovative Drug Companies' New Transaction Mode in Capital Winter
CompanyDeals

NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter

March 9, 2025
Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development
Company

Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development

March 9, 2025
Sino Biopharmaceutical Licenses Nanjing Delova's QP001 for Mainland China Rights
CompanyDeals

Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights

March 7, 2025
Fosun Pharmaceutical's Foritinib Accepted for Review by China's NMPA for NSCLC Treatment
CompanyDrug

Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment

March 7, 2025
Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16
CompanyDrug

Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16

March 7, 2025
Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease
CompanyDrug

Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease

March 7, 2025
Johnson & Johnson Terminate Phase III VENTURA Program for Aticaprant in adjunctive treatment of MDD
CompanyDrug

Johnson & Johnson Terminate Phase III VENTURA Program for Aticaprant in adjunctive treatment of MDD

March 7, 2025
Gan & Lee Pharmaceuticals Joins Brazil's PDP for Localized Insulin Production
CompanyDrug

Gan & Lee Pharmaceuticals Joins Brazil’s PDP for Localized Insulin Production

March 7, 2025
Insilico Medicine's AI-Discovered Drug Rentosertib Approved for Clinical Trials
CompanyDrug

Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials

March 7, 2025
4C Medical Lands $175M Series D to Advance AltaValve TMVR System
CompanyDeals

4C Medical Lands $175M Series D to Advance AltaValve TMVR System

March 7, 2025
Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences
Company

Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences

March 7, 2025
Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform
CompanyDeals

Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform

March 7, 2025
1 2 … 23 24 25 26 27 … 31 32
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up